Immutep targets $100m for lung cancer drug trial tests
Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results